Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2024 (Event date: September 12, 2024)
Context: The filing serves to incorporate a press release regarding a scheduled FDA Advisory Panel meeting for the Company's ProSense® device.
Key Financial Metrics
This filing is an event-based report and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No financial material changes are reported in this document. The primary material event is the announcement of a regulatory milestone:
- Event: FDA Advisory Panel meeting scheduled for November 7, 2024.
- Subject: Marketing Authorization of ProSense® for early-stage low-risk breast cancer.
Guidance, Outlook, and Risks
Outlook: The Company anticipates a regulatory decision following the November 7, 2024 advisory panel meeting regarding the ProSense® device.
Risks and Contingencies: The filing incorporates "Forward Looking Statements" from the attached press release (Exhibit 99.1). While the specific text of these statements is not included in the Form 6-K body, the inclusion indicates standard risks associated with regulatory approvals and future projections.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the outcome of the FDA Advisory Panel meeting scheduled for November 7, 2024.
- Review the full text of the press release (Exhibit 99.1) for specific details on the "Forward Looking Statements" and associated risk factors.
- Monitor subsequent filings for the FDA's final marketing authorization decision for ProSense®.
- Check the Company's most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K contains none.